UnitedHealth Group Inc (UNH) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

UnitedHealth Group Inc (UNH)

411.04

+2.52 (0.62%)

as of Jun 15, 2026, 8:00:00 pm Market Open.

287 watching

Investor Insights

Jun 14, 2026, 12:00 am

This summary was created by AI, based on 43 opinions in the last 12 months.

UnitedHealth Group Inc (UNH-N) has faced considerable challenges over the past year, reflected in its declining stock price and regulatory scrutiny. Experts note that while the company is fundamentally strong with significant vertical integration in the U.S. healthcare system, it has been impacted by rising medical costs, regulatory pressures, and changes in Medicare reimbursement rates. The new CEO’s leadership is viewed as a positive factor that could guide the company through its current difficulties, but many analysts express caution due to the speculative nature of recent issues and the stock's volatility. Some believe the downturn creates buying opportunities, suggesting that long-term growth may be achievable if operational concerns are resolved. Overall, the sentiment is mixed, with a few experts optimistic about potential recovery while others advise caution until more clarity emerges.

Consensus

Cautious

Valuation

Undervalued

Similar

Cvs, CVS

DON'T BUY

Caller works at a health facility where UNH is rejecting claims from a significant number of patients

That news is distressing. That's unfair. He switched to Humana for coverage, but also bought Humana shares.

Wealthica Track your Stocks in your Watch List

BUY

She just added shares. It's been underperforming the market, but still has growth being #1 in health insurance in the U.S. Will enjoy earnings growth this year whatever happenings to the economy.

BUY

Like Pepsi, it's a steady earner and trades at the same 21x PE. Lots of cash flow and higher ROE than peers. Will do well in a tough economy.

TOP PICK

Defensive stock that is good for long term investors.
Likes dynamics of healthcare industry - believes demand for healthcare will remain strong.
Very well run company.
Don’t think this operates in Canada
Continually growing business.

BUY

Strong sector with demand for healthcare services excellent.
Largest health insurance provider in USA (within sector).
130 million customers in the USA.
Aging population creating demand for health insurance.
Good for the long term investor.
Would recommend buying.

HOLD

He trimmed it last September to decrease his overall healthcare allocation. UNH has slowing topline and profits, but it's still growing with secular tailwinds, and rising enrollments, so he's holding on. UNH has outperformed all healthcare over the last 12 months by 40%.

DON'T BUY

It provides health care and healthcare insurance products. It is difficult to understand and is just one bad news headline away from destroying its business. He prefers to stay away from Healthcare and has only one - Stryker.

HOLD

He looks for strong growth, cashflows, and stability. He owns, and would recommend looking at.

Wealthica Track your Stocks in your Watch List

BUY

The U.S. Healthcare sector is a good place to be. He prefers CVS but UNH is also excellent. More money is spent on healthcare in the U.S. than anywhere else in the world.

BUY

Allan Tong’s Discover Picks UNH is a one-stop shop for health in America by operating insurance, pharmacies and clinics. If there is a caveat, it’s that possible UNH stock has enjoyed too much of a run lately. However, since Boxing Day have retraced from $530 to $489. The street has 11 buys and three holds at a $602.64 price target which is 23% higher than now. Read 3 Defensive Stocks to Catch the Rebound for our full analysis.

BUY

Currently long on the stock as believes healthcare good sector. Required service in healthcare. Value of stock attractive (24x earnings). Small dividend yield at ~2% that is safe.

HOLD

A leader. Always outperforms the S&P 500. Healthcare performed quite well last year, and now there's a bit of rotation out and into higher beta names. Next 12-18 months, you still want healthcare in your portfolio. Defensive capabilities along with growth. 20x forward earnings, 12% growth rate. Yield is 1.3%, which will grow.

DON'T BUY

UNH vs. ELV A better choice is ELV, the old Anthem. It comes down to valuation. While the metrics are similar, the PE is 22-23x for UNH, yet 6 points lower for ELV. Virtually identical performance.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Oct 11/22, Up 0%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with UNH has triggered its stop at $500. To remain disciplined, we recommend covering the position at this time.

DON'T BUY

Great. A Republican mid-term win should solidify this and other healthcare insurers, as there won't be the pricing pressure from the Democrats. On valuation, he prefers ELV (the old Anthem) at 6 multiple points cheaper.

Showing 121 to 135 of 285 entries

Most Recent Experts

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Gordon Reid

GoodReid Investment Counsel

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

UnitedHealth Group Inc (UNH)